WEREWOLF THERAPEUTICS
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
WEREWOLF THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.werewolftx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
128.17 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Anavo Therapeutics
Anavo Therapeutics provides therapeutic potential of human phosphatase biology.
Aortyx
The ultimate solution for aortic diseases
Janpix
Janpix operates as an oncology-focused startup.
Nuntius Therapeutics
Nuntius Therapeutics is pioneering a new class of targeted RNA, DNA and CRISPR therapies.
Quell Therapeutics
Quell Therapeutics is a cell therapy company
Caraway Therapeutics
Rheostat Therapeutics is a bio therapeutics company.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Swing Therapeutics
Swing Therapeutics provides digital therapeutics for people with chronic conditions.
Teewinot Life Sciences
Teewinot Life Sciences Corporation is a biopharmaceutical company
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
MPM Capital
MPM Capital investment in Series B - Werewolf Therapeutics
UPMC Enterprises
UPMC Enterprises investment in Series B - Werewolf Therapeutics
Longwood Fund
Longwood Fund investment in Series B - Werewolf Therapeutics
DC Investment Partners
DC Investment Partners investment in Series B - Werewolf Therapeutics
Taiho Ventures
Taiho Ventures investment in Series B - Werewolf Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Werewolf Therapeutics
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Series B - Werewolf Therapeutics
Soleus Capital
Soleus Capital investment in Series B - Werewolf Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Werewolf Therapeutics
Adage Capital Management
Adage Capital Management investment in Series B - Werewolf Therapeutics
Official Site Inspections
http://www.werewolftx.com Semrush global rank: 2.63 M Semrush visits lastest month: 6.5 K
- Host name: 78.124.199.104.bc.googleusercontent.com
- IP address: 104.199.124.78
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Werewolf Therapeutics"
Werewolf Therapeutics - Crunchbase Company Profile …
Contact Email [email protected] Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics …See details»
Investors | Werewolf Therapeutics, Inc.
Jun 6, 2024 Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s …See details»
Our Team | Werewolf Therapeutics Inc.
Randi Isaacs, M.D., has served as our Chief Medical Officer since November 2020. Previously, from May 2010 until November 2020, Dr. Isaacs held roles of increasing responsibility as Clinical Program Leader, Deputy Site Head, and, …See details»
Werewolf Therapeutics - LinkedIn
Werewolf Therapeutics Biotechnology Research Watertown, Massachusetts 5,394 followers Advancing a pipeline of next generation, transformative immuno-stimulatory medicines for cancer patients.See details»
Werewolf Therapeutics
Real-world organization heading rapidly towards a clinical pipeline. “We have a proven leadership team that includes people with a lot of experience from biotech and big pharma companies, …See details»
Werewolf Therapeutics Announces Promising New Development
Oct 31, 2024 To learn more about the Company’s platform and immunology approach, visit www.werewolftx.com. About Werewolf Therapeutics Werewolf Therapeutics, Inc., is an …See details»
Werewolf Therapeutics Reports Third Quarter 2021 Financial …
The increase in research and development expenses was primarily due to increased manufacturing, contract research organization, and personnel expenses incurred to advance …See details»
Investors - Werewolf Therapeutics, Inc.
May 1, 2024 To learn more visit www.werewolftx.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that involve …See details»
Werewolf Therapeutics to Present at the H.C. Wainwright …
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company …See details»
Werewolf Therapeutics to Present First-of-Its-Kind Data
Apr 4, 2024 To learn more about our platform and immunology approach, visit www.werewolftx.com. About Werewolf Therapeutics. Werewolf Therapeutics, Inc., is an …See details»
Our Science | Werewolf Therapeutics Inc.
INDUKINE™ molecules are systemically administered in an inactive form and, upon entering the tumor microenvironment, are selectively activated to deliver the full biological potency of …See details»
Werewolf Therapeutics Announces WTX-124 Clinical Abstract
Apr 24, 2024 To learn more visit www.werewolftx.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that involve …See details»
Investors - Werewolf Therapeutics, Inc.
Jun 25, 2024 To learn more visit www.werewolftx.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that involve …See details»
Werewolf Therapeutics Presents Preliminary Monotherapy Data …
Nov 3, 2023 Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy …See details»
Werewolf Therapeutics Announces Publication of Data
Mar 16, 2022 To learn more visit www.werewolftx.com. Cautionary Note Regarding Forward-Looking Statements. This press release contains forward-looking statements that involve …See details»
Werewolf Therapeutics Reports Second Quarter 2022 Financial …
Aug 11, 2022 The increase in research and development expenses was primarily due to manufacturing expenses incurred to support the production of preclinical and future clinical …See details»
Our Approach | Werewolf Therapeutics Inc.
WTX-330 is a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE TM molecule that is being developed to minimize the severe toxicities that have been observed …See details»
Werewolf Therapeutics to Participate at the Jefferies Global …
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company …See details»
Werewolf Therapeutics Announces Clinical Trial - GlobeNewswire
Aug 18, 2021 [email protected]. Media Contact: Amanda Sellers VERGE Scientific Communications 301.332.5574 [email protected] ...See details»